GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody—Response

Christian A. Gerdes and Pablo Umaña

We are pleased that Dr. Modjtahedi found our work on GA201 interesting. The origin of the CDR sequences of GA201 based on the published sequences of the ICR62 antibody is clearly mentioned in our publication (1). Likewise, previous publications describing the properties of ICR62 were also cited in the article.

Equivalent EGFR binding of the humanized antibody versus the chimeric antibody with the original, complete variable regions of ICR62 is shown in Fig. 1. Increased binding affinity to FcgRIII as a result of Fc glycoengineering is clearly documented in this and many other publications (1–3). The safety profile and initial clinical activity of GA201 in humans has been described (4). Finally, regarding the contribution of glycoengineering to the superior efficacy of GA201 versus cetuximab in preclinical tumor models, please see demonstration in Fig. 2. In vitro activity comparisons and additional in vivo comparisons are already described in our publication (ref. 1, figs. 3 and 4).

Authors’ Affiliation: Roche Glycart AG, pRED, Schlieren, Switzerland

Corresponding Authors: Christian A. Gerdes, Roche Glycart AG, Wagistrasse 18 CH-8952 Schlieren, Switzerland, Phone: 41-44-755-6148; Fax: 41-44-755-6165; E-mail: christian.gerdes@roche.com; and Pablo Umaña, pablo.umana@roche.com

doi: 10.1158/1078-0432.CCR-13-2699

©2014 American Association for Cancer Research.

References

GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody—Response

Christian A. Gerdes and Pablo Umaña

*Clin Cancer Res* 2014;20:1055.

**Updated version**  Access the most recent version of this article at: [http://clincancerres.aacrjournals.org/content/20/4/1055](http://clincancerres.aacrjournals.org/content/20/4/1055)

**Cited articles**  This article cites 4 articles, 4 of which you can access for free at: [http://clincancerres.aacrjournals.org/content/20/4/1055.full.html#ref-list-1](http://clincancerres.aacrjournals.org/content/20/4/1055.full.html#ref-list-1)

**E-mail alerts**  Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.